- Home
- BIOA vs TIL Comparison
BIOA vs TIL Comparison
Compare BIOA & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- TIL
- Stock Information
- Founded
- BIOA 2015
- TIL 2018
- Country
- BIOA United States
- TIL United States
- Employees
- BIOA N/A
- TIL N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- BIOA Health Care
- TIL Health Care
- Exchange
- BIOA Nasdaq
- TIL Nasdaq
- Market Cap
- BIOA 175.7M
- TIL 177.1M
- IPO Year
- BIOA 2024
- TIL 2021
- Fundamental
- Price
- BIOA $8.00
- TIL $18.94
- Analyst Decision
- BIOA Hold
- TIL Strong Buy
- Analyst Count
- BIOA 4
- TIL 5
- Target Price
- BIOA $7.33
- TIL $100.67
- AVG Volume (30 Days)
- BIOA 548.4K
- TIL 109.9K
- Earning Date
- BIOA 11-06-2025
- TIL 11-12-2025
- Dividend Yield
- BIOA N/A
- TIL N/A
- EPS Growth
- BIOA N/A
- TIL N/A
- EPS
- BIOA N/A
- TIL N/A
- Revenue
- BIOA $3,863,000.00
- TIL N/A
- Revenue This Year
- BIOA N/A
- TIL N/A
- Revenue Next Year
- BIOA N/A
- TIL N/A
- P/E Ratio
- BIOA N/A
- TIL N/A
- Revenue Growth
- BIOA N/A
- TIL N/A
- 52 Week Low
- BIOA $2.88
- TIL $10.80
- 52 Week High
- BIOA $25.33
- TIL $44.50
- Technical
- Relative Strength Index (RSI)
- BIOA 80.25
- TIL 45.86
- Support Level
- BIOA $5.05
- TIL $18.10
- Resistance Level
- BIOA $5.52
- TIL $20.32
- Average True Range (ATR)
- BIOA 0.33
- TIL 1.56
- MACD
- BIOA 0.14
- TIL 0.20
- Stochastic Oscillator
- BIOA 83.10
- TIL 37.96
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.